[ad_1]
Hyderabad-based pharmaceutical company Hetero on Sunday announced the regulatory approval and launch of its generic drug Covifor for the treatment of COVID-19 disease. The company said it had received approval of regulator Drug Controller General of India (DCGI) for the manufacturing and marketing of investigational antiviral medicine Remdesivir. Hetero said its generic version of US-based Gilead Science’s experimental COVID-19 treatment Remdesivir will be marketed under brand name Covifor in India.
“In the light of increasing COVID-19 cases in India, the approval of Covifor (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,” said Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies.
“We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against COVID-19,” he said.
Remdesivir has received approval of the country’s drug regulator “for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease”, Hetero said. Covifor will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.
The product is launched under a licensing agreement with Gilead Sciences to expand access to COVID-19 treatment in low- and middle-income countries, Hetero said.
Hetero is a generics pharmaceutical company with presence in more than 126 countries.
[ad_2]
Source link